1: Takeuchi K, Mohammad S, Ozaki T, Morioka E, Kawaguchi K, Kim J, Jeong B, Hong JH, Lee KJ, Ikeda M. Serotonin-2C receptor involved serotonin-induced Ca²⁺ mobilisations in neuronal progenitors and neurons in rat suprachiasmatic nucleus. Sci Rep. 2014 Feb 17;4:4106. doi: 10.1038/srep04106. PubMed PMID: 24531181; PubMed Central PMCID: PMC3925950.
2: Murray F, Hutson PH. Hippocampal Bcl-2 expression is selectively increased following chronic but not acute treatment with antidepressants, 5-HT(1A) or 5-HT(2C/2B) receptor antagonists. Eur J Pharmacol. 2007 Aug 13;569(1-2):41-7. Epub 2007 May 13. PubMed PMID: 17582397.
3: Jenck F, Bös M, Wichmann J, Stadler H, Martin JR, Moreau JL. The role of 5-HT2C receptors in affective disorders. Expert Opin Investig Drugs. 1998 Oct;7(10):1587-99. PubMed PMID: 15991903.
4: Hutson PH, Barton CL, Jay M, Blurton P, Burkamp F, Clarkson R, Bristow LJ. Activation of mesolimbic dopamine function by phencyclidine is enhanced by 5-HT(2C/2B) receptor antagonists: neurochemical and behavioural studies. Neuropharmacology. 2000 Sep;39(12):2318-28. PubMed PMID: 10974315.
5: Bristow LJ, O'Connor D, Watts R, Duxon MS, Hutson PH. Evidence for accelerated desensitisation of 5-HT(2C) receptors following combined treatment with fluoxetine and the 5-HT(1A) receptor antagonist, WAY 100,635, in the rat. Neuropharmacology. 2000 Apr 27;39(7):1222-36. PubMed PMID: 10760364.
6: Bromidge SM, Dabbs S, Davies DT, Duckworth DM, Forbes IT, Ham P, Jones GE, King FD, Saunders DV, Starr S, Thewlis KM, Wyman PA, Blaney FE, Naylor CB, Bailey F, Blackburn TP, Holland V, Kennett GA, Riley GJ, Wood MD. Novel and selective 5-HT2C/2B receptor antagonists as potential anxiolytic agents: synthesis, quantitative structure-activity relationships, and molecular modeling of substituted 1-(3-pyridylcarbamoyl)indolines. J Med Chem. 1998 May 7;41(10):1598-612. PubMed PMID: 9572885.